Home
/

What is a Lipoprotein fractionation Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

Lipoprotein fractionation separates and quantifies all major lipoprotein classes—VLDL, IDL, LDL (with size distribution), HDL, remnants, and Lp(a)—providing a detailed map of how the body packages and traffics fats beyond standard lipid panels. Elevated small dense LDL and high LDL particle number are associated with increased plaque formation and insulin resistance, while very low fractions may reflect malnutrition or liver disease. This cascade view connects liver fat handling and vascular inflammation to refined cardiovascular risk that LDL-C alone may miss.

Read more →
Table of contents

Sorting the Lipoprotein Cascade Into Particle Classes and Sizes

Lipoprotein fractionation blood testing profiles the different particles that carry fats in your blood. Lipoproteins are tiny packages of cholesterol and triglyceride wrapped in proteins (apolipoproteins), produced by the liver and intestine and constantly remodeled as they circulate. This test separates and quantifies major classes—VLDL, IDL, LDL, HDL—along with remnants and often lipoprotein(a). It shows how particles are distributed by size, density, and composition, giving a more detailed picture than a standard lipid panel, which sums cholesterol within broad categories.

The pattern of fractions shows how your body traffics fats and cholesterol: which particles tend to deliver them to tissues and artery walls, and which help carry them away. Triglyceride-rich remnants and small, dense LDL are more likely to penetrate vessel lining, while HDL participates in returning cholesterol to the liver (reverse cholesterol transport). Lipoprotein(a) carries an added protein that can bind to vessel surfaces and transport oxidized lipids. Together, the fractions reflect the quality of lipid transport—how efficiently fats are packaged, remodeled, and cleared—offering a functional view beyond total cholesterol.

Why a Particle-Level View Beats a Standard Lipid Panel

Lipoprotein fractionation shows how your body packages and moves fats—partitioning cholesterol and triglycerides into LDL, HDL, VLDL, and their particle sizes. It goes beyond a basic lipid panel to reveal the balance between atherogenic particles (small, dense LDL and remnant lipoproteins) and protective ones (larger LDL and robust HDL). This balance affects arterial plaque formation, insulin sensitivity, fatty liver, and pancreatitis risk.

It maps how the body packages and traffics fats and cholesterol for energy, membranes, and hormones. Because small particles and remnants penetrate arteries, this profile refines cardiovascular risk and mirrors hepatic metabolism, insulin sensitivity, and vascular inflammation.

Reading Atherogenic vs. Protective Fractions Across the Panel

Reports typically categorize particle numbers and sizes as low, intermediate, or high risk. Within reference ranges patterns cluster toward fewer atherogenic particles, a predominance of larger LDL, lower remnants, and higher functional HDL particles—think "low" for the bad actors and "healthy-high" for HDL.

When the atherogenic fractions are low, arteries face less cholesterol deposition and inflammation. Most people feel no symptoms; if lipoproteins are globally very low, it can reflect malnutrition, hyperthyroidism, advanced liver disease, or rare genetic hypolipidemias, sometimes with fatigue, weight loss, or fat-soluble vitamin issues. Children rarely have pathologically low fractions unless genetic; women often show more favorable HDL profiles.

Low values usually reflect a low atherogenic burden—low LDL particle number, few small dense LDL and remnants—with a shift to larger, buoyant particles. Physiology suggests efficient clearance and insulin sensitivity, with reduced plaque propensity. Children and premenopausal women commonly display this profile.

Being in range suggests balanced transport: LDL particle number in the mid-to-low span, predominance of larger LDL and HDL, and normal remnants. This supports steady energy use and membrane repair without particle crowding, favoring stable vascular function. Many experts favor the lower half for LDL particle number.

When atherogenic fractions are high—especially small dense LDL, LDL particle number, and VLDL remnants—plaque risk rises, often alongside insulin resistance, central adiposity, hypothyroidism, kidney disease, or familial disorders. Symptoms are usually silent until angina, heart attack, or stroke; tendon xanthomas and fatty liver can appear in severe cases. Men more often display small dense LDL; pregnancy physiologically raises triglyceride-rich particles and remnants.

High values usually reflect excess atherogenic fractions—high LDL particle number, abundant small dense LDL, remnants, and elevated VLDL. This stems from hepatic overproduction, impaired lipolysis, and insulin resistance, seen with metabolic syndrome, diabetes, hypothyroidism, kidney disease, aging, and more often in men. Late pregnancy physiologically raises triglyceride-rich particles.

Assay Method, Fasting, and Other Sources of Variation

Results vary by assay (NMR, ion mobility, gradient gel), fasting status, acute illness, and drugs (statins, fibrates, estrogen, steroids). Reference ranges differ by lab. LDL-C and particle number may be discordant; interpret with standard lipids and clinical context.

Big picture, fractionation links lipid transport to metabolism, endocrine status, liver health, and vascular biology. It refines cardiovascular risk beyond LDL-C alone and connects to long-term outcomes including atherosclerotic disease, NAFLD, and pancreatitis.

FAQs

Lipoprotein fractionation is a specialized blood test that separates cholesterol- and triglyceride-carrying particles into their major classes and subgroups, such as VLDL, IDL, LDL, and HDL. Unlike a standard cholesterol test, which measures total cholesterol, LDL-C, HDL-C, and triglycerides, fractionation provides detailed information about the size, number, and density of these particles. This allows for a more precise assessment of cardiovascular risk by identifying atherogenic patterns, such as small, dense LDL or cholesterol-rich remnants, which may not be apparent in standard lipid panels.

Lipoprotein fractionation reveals hidden cardiovascular risk by detecting small, dense LDL particles and triglyceride-rich remnants that are more likely to penetrate artery walls and promote plaque formation. These atherogenic particles are often missed by standard cholesterol tests. By mapping the distribution and size of lipoprotein particles, fractionation uncovers patterns linked to insulin resistance, metabolic syndrome, and inherited lipid disorders, providing a clearer picture of atherosclerotic risk.

Knowing your LDL particle size and number through lipoprotein fractionation helps clarify your risk for heart disease. Small, dense LDL particles are more atherogenic and associated with higher cardiovascular risk, while larger, buoyant LDL particles are less harmful. A high LDL particle number, even with normal LDL-C, can indicate increased risk. This information guides treatment intensity and helps monitor response to lifestyle changes or medications.

Lipoprotein fractionation detects insulin resistance patterns by identifying a rise in small, dense LDL particles and unfavorable shifts in HDL subclasses. Insulin resistance often leads to hepatic overproduction of triglyceride-rich VLDL and reduced clearance of atherogenic particles. These changes are reflected in the fractionation profile, signaling metabolic dysfunction even before glucose abnormalities appear.

Triglyceride-rich remnants such as VLDL and IDL are important because they are strongly linked to atherosclerosis. Lipoprotein fractionation highlights these particles, which are often elevated in insulin resistance, metabolic syndrome, and certain inherited disorders. High levels of VLDL and IDL remnants indicate increased risk for plaque buildup and cardiovascular events, even if LDL-C appears normal.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
  2. Feingold, K. R. (2026). Utility of advanced lipoprotein testing in clinical practice. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK355893/
  3. Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson, P. W. F., & D'Agostino, R. B. (2007). LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. Journal of Clinical Lipidology, 1(6), 583-592. https://doi.org/10.1016/j.jacl.2007.10.001
  4. Nordestgaard, B. G. (2016). Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circulation Research, 118(4), 547-563. https://doi.org/10.1161/CIRCRESAHA.115.306249
  5. Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey